Search in:

Expert Review of Vaccines Volume 23, 2024 - Issue 1

Submit an article Journal homepage

Open access

1,590

Views

CrossRef citations to date

Altmetric

Review

The use of electroporation to deliver DNA-based vaccines

Denis N Kisakova Department of bioengineering, State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, Novosibirsk region, RussiaView further author information

Igor M. Belyakovb Department of medico-biological disciplines, Moscow University for Industry and Finance “Synergy”, Moscow, RussiaCorrespondence[email protected]
View further author information

Lubov A Kisakovaa Department of bioengineering, State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, Novosibirsk region, RussiaView further author information

Vladimir A Yakovleva Department of bioengineering, State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, Novosibirsk region, RussiaView further author information

Elena V Tigeevaa Department of bioengineering, State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, Novosibirsk region, RussiaView further author information

Larisa I Karpenkoa Department of bioengineering, State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, Novosibirsk region, RussiaView further author information

Pages 102-123 | Received 29 Aug 2023, Accepted 05 Dec 2023, Published online: 18 Dec 2023

Cite this article
https://doi.org/10.1080/14760584.2023.2292772
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF View EPUB EPUB

Figures & data

Figure 1. Mechanism of enhancing immune response by electroporation.

Table 1. Use of EP to deliver DNA vaccines in clinical trials.

Download CSV Display Table

Table 2. The use of EP in the delivery of DNA vaccines against viral infections.

Download CSV Display Table

Table 3. The use of EP in the delivery of DNA vaccines against bacterial and parasitic infections.

Download CSV Display Table

VGX-3100 and electroporation in treating Patients with HIV-Positive high-grade anal lesions | ClinicalTrials.Gov [Internet]. [cited 2023 Oct 6]. Available from: https://clinicaltrials.gov/study/NCT03603808?tab=table.

Google Scholar

Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers | ClinicalTrials.Gov [Internet]. [cited 2023 Oct 6]. Available from: https://clinicaltrials.gov/study/NCT04336410?tab=table.

Google Scholar

A study to evaluate Safety & immunogenicity of SARS-CoV-2 DNA vaccine delivered intramuscularly followed by electroporation for COVID-19 | ClinicalTrials.Gov [Internet]. [cited 2023 Oct 6]. Available from: https://clinicaltrials.gov/study/NCT05102643?tab=table.

Google Scholar

A first-in-human study to evaluate Safety, tolerability, reactogenicity, and immunogenicity of JNJ-64300535, a DNA vaccine, administered by electroporation-mediated intramuscular injection, in participants with chronic hepatitis B who are on stable Nucleos(t)Ide therapy and virologically suppressed | ClinicalTrials.Gov [Internet]. [cited 2023 Oct 6]. Available from: https://clinicaltrials.gov/study/NCT03463369?tab=table.

Google Scholar

Study of PENNVAXTM-B (gag, Pol, Env) + electroporation in HIV-1 infected Adult participants | ClinicalTrials.Gov [Internet]. [cited 2023 Oct 6].

Google Scholar

Safety, tolerability and immunogenicity of INO-4800 followed by electroporation in healthy volunteers for COVID19 | ClinicalTrials.Gov [Internet]. [cited 2023 Oct 6]. Available from: https://clinicaltrials.gov/study/NCT04447781?tab=table.

Google Scholar

Safety and immunogenicity of HIV DNA-C CN54ENV and recombinant HIV CN54gp140 vaccines in healthy volunteers | ClinicalTrials.Gov [Internet]. [cited 2023 Oct 6]. Available from: https://clinicaltrials.gov/study/NCT02589795?tab=table.

Google Scholar

GLS-5700 in Healthy Volunteers | ClinicalTrials.gov [Internet]. [cited 2023 Nov 15]. Available from: https://clinicaltrials.gov/study/NCT02809443.

Google Scholar

Dose-finding, Safety study of plasmid DNA Therapeutic vaccine to treat cervical intraepithelial neoplasia | ClinicalTrials.Gov [Internet]. [cited 2023 Nov 15]. Available from: https://clinicaltrials.gov/study/NCT02139267.

Google Scholar

The Safety and immunogenicity of the DNA-GTU vaccine administered to HIV-infected Patients on ART vs placebo | ClinicalTrials.Gov [Internet]. [cited 2023 Nov 15]. Available from: https://clinicaltrials.gov/study/NCT02457689?tab=table.

Google Scholar

Study of a DNA-based Venezuelan equine encephalitis virus DNA vaccine administered by electroporation in healthy volunteers | ClinicalTrials.Gov [Internet]. [cited 2023 Nov 15]. Available from: https://clinicaltrials.gov/study/NCT01984983?tab=table.

Google Scholar

A phase II trial to assess the Safety and immunogenicity of DNA priming administered by the ID Zetajet® with or without ID derma VaxTM electroporation followed by IM MVA boosting in healthy volunteers in Tanzania and Mozambique | ClinicalTrials.Gov [Internet]. [cited 2023 Nov 15]. Available from: https://clinicaltrials.gov/study/NCT01697007?tab=table.

Google Scholar

Evaluating the Safety of and immune response to an HIV vaccine followed by booster, administered by two devices, in HIV-Uninfected adults | ClinicalTrials.Gov [Internet]. [cited 2023 Nov 15]. Available from: https://clinicaltrials.gov/study/NCT01260727.

Google Scholar

A study of DNA vaccine with electroporation for the prevention of disease caused by H1 and H5 influenza virus | ClinicalTrials.Gov [Internet]. [cited 2023 Oct 6]. Available from: https://clinicaltrials.gov/study/NCT01405885?tab=table.

Google Scholar

Study of PENNVAXTM-B (gag, Pol, Env) + electroporation in HIV-1 infected Adult participants | ClinicalTrials.Gov [Internet]. [cited 2023 Nov 15]. Available from: https://clinicaltrials.gov/study/NCT01082692?tab=table.

Google Scholar

Study of VGX-3400X, H5N1 avian influenza virus DNA plasmid + electroporation in healthy adults | ClinicalTrials.Gov [Internet]. [cited 2023 Nov 15]. Available from: https://clinicaltrials.gov/study/NCT01142362.

Google Scholar

Petkov S, Kilpeläinen A, Bayurova E, et al. HIV-1 protease as DNA immunogen against Drug resistance in HIV-1 infection: DNA Immunization with Drug resistant HIV-1 protease protects mice from challenge with protease-expressing cells. Cancers (Basel). 2022;15(1):15. doi: 10.3390/cancers15010238

Your download is now in progress and you may close this window

Login or register to access this feature

The use of electroporation to deliver DNA-based vaccines

Figures & data

Table 1. Use of EP to deliver DNA vaccines in clinical trials.

Table 2. The use of EP in the delivery of DNA vaccines against viral infections.

Table 3. The use of EP in the delivery of DNA vaccines against bacterial and parasitic infections.

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date